Cardiovascular Disease Posttransplant

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 430-444

  Pham, Phuong Thu T ^a   Pham, Phuong Chi T ^a,b   Danovitch, Gabriel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

anemia; Cardiovascular disease posttransplant; dyslipidemia; hyperhomocysteinemia; inflammation; new onset diabetes mellitus after transplantation; obesity; oxidative stress; posttransplant hypertension; proteinuria

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; GEMFIBROZIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; INSULIN; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATEGLINIDE; PHENYTOIN; PYRROLE DERIVATIVE; RAPAMYCIN; REPAGLINIDE; RIFAMPICIN; SIMVASTATIN; STEROID; TACROLIMUS; UNINDEXED DRUG;

ANEMIA; ARTERY CALCIFICATION; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIALYSIS; DYSLIPIDEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; KIDNEY TRANSPLANTATION; LUNG EDEMA; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY TRANSPLANTATION; PREVALENCE; PROGNOSIS; RISK FACTORS; WORLD HEALTH;

EID: 34347259174     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.005     Document Type: Article

References (65)

1. Meier-Kriesche H.U., Schold J.D., and Kaplan B. Preservation of long-term renal allograft survival: a challenge for the years to come. Am J Transplant 5 (2005) 632-633
2. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 31 (2004) 1285-1295
3. Simmons E.M., Langone A., and Sezer M.T. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79 (2005) 914-919
4. Ducloux D., Kazory A., and Chalopin J.M. Predicting coronary heart disease in renal transplant recipients. A prospective study. Kidney Int 66 (2004) 441-447
5. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 82 (2006) 603-611
6. Kalil R.S., Hudson S.L., and Gaston R.S. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?. Am J Transplant 3 (2003) 79-81
7. Humar A., Gillingham K., Payne W.D., et al. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 70 (2000) 310-313
8. Kasiske B.L., Anjum S., Shah R., et al. Hypertension after transplantation. Am J Kidney Dis 43 (2004) 1071-1081
9. Premasathian N.C., Muehrer R., Brazy P.C., et al. Blood pressure control in kidney transplantation. Therapeutic implications. J Hum Hypertens 18 (2004) 871-877
10. Opelz G., Wujciak T., Ritz E., et al. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 53 (1998) 217-222
11. Kreis H., Oberbauer R., and Campistol J.M. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809-817
12. Pascual J., Van Hooff J.P., and Salmela K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplantation. Transplantation 85 (2006) 55-61
13. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 (2000) 1735-1743
14. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
15. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
16. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive kidney disease: results from the AASK trial. JAMA 288 (2002) 2421-2431
17. De Champlain, Karas M., Nguyen P., et al. Different effects of nifedipine and amlodipine on circulating catecholamines levels in essential hypertensive patients. J Hypertens 16 (1998) 1357-1369
18. Pham P.T., Danovitch G.M., Pham P.C., et al. The medical management of the renal transplant recipient. In: Johnson R.J., and John Feehally (Eds). Comprehensive clinical nephrology. 3rd ed (2007), Mosby, Philadelphia 1848-1853
19. Kasiske B.L., Snyder J.J., Gilbertson D., et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178-185
20. Teutonico A., Schena P.F., and Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16 (2005) 3128-3135
21. Zhang N., Su D., Qu S., et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function in transplants. Diabetes 55 (2006) 2429-2436
22. Jindal R.M., and Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation. 70 Suppl 11 (2000) SS58-SS63
23. Cheng A.Y.Y., and Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172 (2005) 213-226
24. Hatorp V., Hansen K.T., and Thomsen M.S. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 43 (2003) 649-660
25. Niemi M., Backman J.T., Neuvonen P.J., et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68 (2000) 495-500
26. Collins R., Peto R., Armitage J., and Heart Protection Collaborative Group. Heart Protection Study of cholesterol-lowering with simvastatin in 20, 536 high-risk individuals: a randomized-placebo controlled trial. Lancet 360 (2002) 7-22
27. Messerli A.W., Aronow H.D., and Sprecker D.L. The Lescol Intervention Prevention Study (LIPS): start all patients on statin early after PCI. Cleve Clin J Med 70 (2003) 561-566
28. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
29. Holdaas H., Fellstrom B., Jardine A.G., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20 (2005) 974-980
30. Fellstrom B., Holdaas H., Jardine A.G., et al. Effect of fluvastatin end points in the Assessment of Lescol in renal Transplantation (ALERT) trial. Kidney Int 66 (2004) 1549-1555
31. Masterson R., Hewitson T., Leikis M., et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 80 (2005) 332-338
32. Ballantyne C.M., Corsini A., Davidson M.H., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
33. Murdoch D., and Scott L.J. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. Am J Cardiovasc Drugs 4 (2004) 405-422
34. Puthenparumpil J.J., Keough-Ryan T., Kiberd M., et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 37 (2005) 1033-1035
35. Canzanello V.J., Schwartz L., Tater S.J., et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus FK(506). Liver Transpl Surg 3 (1997) 1-9
36. Evehart J.E., Lonardero M., Lake J.R., et al. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 4 (1998) 285-296
37. Alexander J.W., Goodman H.R., Gervin K., et al. Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation 78 (2004) 469-474
38. Ducloux D., Motte G., Challier B., et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11 (2000) 134-137
39. Marcucci R., Zanazzi M., Bertoni E., et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients. Transplantation 9 (2003) 1551-1555
40. Cheng K.S., Mikhailidis D.P., Hamilton G., et al. A review of the carotid and femoral intima media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 4 (2002) 528-538
41. Winkelmayer W.C., Kramar R., Curhan G.C., et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 16 (2005) 255-260
42. Bonaa K.H., Njolstad I., Ucland P.M., et al. Homocysteine lowering and cardiovascular event after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
43. Ducloux D., Kazory A., and Chapolin J.M. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 66 (2004) 441-447
44. Winkelmayer W.C., Lorenz M., Kramar R., et al. C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 4 (2004) 1148-1154
45. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
46. Grotz W., Siebig S., Olschewski M., et al. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 77 (2004) 1848-183
47. Lopez-Gomez J.M., Perez-Flores I., Jofre R., et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 1 (2004) 2494-2501
48. Peddi V.R., Dean D.E., Hariharam S., et al. Proteinuria following renal transplantation: crrelation with histopathology and outcome. Transplant Proc 29 (1997) 101-103
49. Fernandez-Fresnedo G., Escallada R., Rodrigo E., et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73 (2002) 1345-1348
50. Roodnat J.I., Mulder P.G., Rischen-Vos J., et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 72 (2001) 438-444
51. Lim H.S., Blann A.D., Chong A.Y., et al. Plasma vascular endothelial growth factor, angiopoietin-1, angiopoeitin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial interventions. Diabetes Care 27 (2004) 2918-2924
52. van den Akker J.M., Wetzels J.F., and Hoitsma A.J. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipiients. Kidney Int 70 (2006) 1355-1357
53. Afzali B., Al-Khoury S., Shah N., et al. Anemia after renal transplantation. Am J Kidney Dis 48 (2006) 519-536
54. Turkowski-Duhem A., Kamar N., Cointault O., et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 80 (2005) 903-909
55. Augustine J.J., Schulak J.A., Bodziak K.A., et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4 (2004) 2001-2006
56. Jaster R., Bittorf T., Klinken S.P., et al. Inhibition of proliferation but not erythroid differentiation of j2E cells by rapamycin. Biochem Pharmacol 51 (1996) 1181-1185
57. Djamali A., Becker Y.T., Simmons W.D., et al. Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 76 (2003) 816-820
58. Imoagene-Oyedeji A.E., Rosas S.E., Doyle A.M., et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 17 (2006) 3240-3247
59. Winkelmayer W.C., Lorenz M., Kramar R., et al. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant 4 (2004) 2075-2081
60. Ishitani M.B., Milliner D.S., Kim D.Y., et al. Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant 5 (2005) 1689-1693
61. Rosas S.E., Mensah K., Weinstein R.B., et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 5 (2005) 1942-1947
62. Litwin M., Wuhl E., Jourdan C., et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16 (2005) 1494-1500
63. Hernandez D., Rufino M., Bartolomei S., et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 67 (2005) 2015-2020
64. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17 (2006) 889-899
65. Opelz G., Zeier M., Laux G., et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17 (2006) 3257-3262